Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03945760 · ClinicalTrials.gov registry record · Early Phase 1
Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects
A Early Phase 1 study of Allergic Contact Dermatitis, sponsored by Wright State Physicians.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT03945760 is a Early Phase 1 study of Allergic Contact Dermatitis that has completed, run by Wright State Physicians. The registered enrollment target is 23 participants, roughly in line with the 24-participant average among 3 other Allergic Contact Dermatitis trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT03945760, a Early Phase 1 study of Allergic Contact Dermatitis, has completed, sponsored by Wright State Physicians.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The treatment of allergic contact dermatitis (ACD) can be unsatisfactory, and that other skin diseases such as atopic dermatitis have an increased likelihood of ACD, improved systemic treatments are needed. This research study explores the effectiveness of Baricitinib in treating Delayed-Type Hypersensitivity (allergic) versus Irritant Skin reactions. Subjects for this study need to be healthy males between the ages of 18 and 40. This study will evaluate this by injecting antigens as well as applying them on top of the skin to the forearm then measure the effects of Baricitinib by skin and blood testing.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Baricitinib
Study Locations (1)
Ohio
- Wright State Physicians - Fairborn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2023-10-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03945760
The ClinicalTrials.gov registry entry for NCT03945760 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 24-participant average among 3 other Allergic Contact Dermatitis trials with a reported enrollment target. The listed sponsor is Wright State Physicians, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Contact Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03945760 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03945760 about?
NCT03945760 is a clinical study titled "Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects". The treatment of allergic contact dermatitis (ACD) can be unsatisfactory, and that other skin diseases such as atopic dermatitis have an increased likelihood of ACD, improved systemic treatments are needed. This research study explores the effectiveness of Baricitinib in treating Delayed-Type Hyper...
What is the current status of trial NCT03945760?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 23 participants. The study started on 2020-09-14. Estimated completion is 2023-10-16.
What conditions does trial NCT03945760 study?
This clinical trial studies the following conditions: Allergic Contact Dermatitis.
What interventions are being tested in trial NCT03945760?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG).
Who is sponsoring clinical trial NCT03945760?
This trial is sponsored by Wright State Physicians, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03945760 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Contact Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.